Table 1. Summary of patient characteristics. Data are expressed as mean (Range).
| Single-dose pharmacokinetics |
Multiple-dose pharmacokinetics |
|||||
|---|---|---|---|---|---|---|
| 1.5 mg·m−2 VSLI (n=5) | 2.0 mg·m−2 VSLI (n=6) | 2.3 mg·m−2 VSLI (n=5) | 2 mg VCR (n=6) | 1.5 mg·m−2 VSLI (n=6) | 1.8 mg·m−2 VSLI (n=6) | |
| Sex | ||||||
| Male | 1 | 2 | 2 | 2 | 2 | 3 |
| Female | 4 | 4 | 3 | 4 | 4 | 3 |
| Age (years) | ||||||
| Median, Range | 64 (56–73) | 53 (37–63) | 45 (18–59) | 54 (22–65) | 41 (19–62) | 41 (28–54) |
| Height (cm) | ||||||
| Median, Range | 168 (153–182) | 162 (154–178) | 168 (155–175) | 164 (160–168) | 166 (157–178) | 167 (156–175) |
| Weight (kg) | ||||||
| Median, Range | 72 (60–82) | 61 (55–69) | 70 (61–85) | 64 (50–75) | 70 (55–85) | 64 (42.5–90) |
| Body surface area (m2) | ||||||
| Median, Range | 1.83 (1.62–1.98) | 1.65 (1.54–1.86) | 1.77 (1.61–2.01) | 1.69 (1.54–1.82) | 1.77 (1.54–2) | 1.69 (1.38–2.01) |
| BMI (kg·m−2) | ||||||
| Median, Range | 25.7 (22.6–27.8) | 23.1 (21.8–24.6) | 24.7 (21.1–28.1) | 23.6 (18.1–27.5) | 25.6 (22–32.4) | 22.7 (17.5–29.4) |
| ECOG status at entry | ||||||
| 0–1 | 5 | 6 | 5 | 6 | 5 | 6 |
| 2 | 0 | 0 | 0 | 0 | 1 | 0 |
| Tumor types | ||||||
| Lymphoma | 4 | 4 | 2 | 6 | 4 | 5 |
| Breast cancer | 1 | 0 | 1 | 0 | 0 | 0 |
| Lung cancer | 0 | 1 | 1 | 0 | 0 | 1 |
| Others (Ewing's sarcoma, Ovarian cancer, Renal carcinoma, laryngocarcinoma) | 0 | 1 | 1 | 0 | 2 | 0 |
| Prior therapy | ||||||
| Chemotherapy | 5 | 6 | 5 | 6 | 6 | 6 |
| Radiotherapy | 3 | 3 | 2 | 0 | 1 | 4 |